The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) closed the day trading at $4.19 down -7.51% from the previous closing price of $4.53. In other words, the price has decreased by -$7.51 from its previous closing price. On the day, 0.76 million shares were traded. YMAB stock price reached its highest trading level at $4.535 during the session, while it also had its lowest trading level at $4.16.
Ratios:
For a better understanding of YMAB, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.35 and its Current Ratio is at 4.77. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On November 18, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $23.
On August 16, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $20.Cantor Fitzgerald initiated its Overweight rating on August 16, 2024, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 07 ’25 when Rossi Michael J sold 3,917 shares for $5.20 per share. The transaction valued at 20,368 led to the insider holds 137,083 shares of the business.
Gad Thomas sold 10,810 shares of YMAB for $56,536 on Mar 07 ’25. The CHIEF BUSINESS OFFICER now owns 202,721 shares after completing the transaction at $5.23 per share. On Mar 07 ’25, another insider, Rajah Vignesh, who serves as the Officer of the company, bought 4,946 shares for $5.20 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, YMAB now has a Market Capitalization of 189789408 and an Enterprise Value of 130031608. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.14 while its Price-to-Book (P/B) ratio in mrq is 2.12. Its current Enterprise Value per Revenue stands at 1.467 whereas that against EBITDA is -5.563.
Stock Price History:
The Beta on a monthly basis for YMAB is 0.46, which has changed by -0.62320143 over the last 52 weeks, in comparison to a change of 0.20799685 over the same period for the S&P500. Over the past 52 weeks, YMAB has reached a high of $16.11, while it has fallen to a 52-week low of $3.55. The 50-Day Moving Average of the stock is -9.33%, while the 200-Day Moving Average is calculated to be -39.00%.
Shares Statistics:
Over the past 3-months, YMAB traded about 198.01K shares per day on average, while over the past 10 days, YMAB traded about 260990 shares per day. A total of 45.25M shares are outstanding, with a floating share count of 33.90M. Insiders hold about 25.16% of the company’s shares, while institutions hold 59.23% stake in the company. Shares short for YMAB as of 1752537600 were 2488963 with a Short Ratio of 12.57, compared to 1749772800 on 2652742. Therefore, it implies a Short% of Shares Outstanding of 2488963 and a Short% of Float of 6.510000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Its stock is currently analyzed by 9.0 different market analysts. The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.18 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$0.63 and -$1.16 for the fiscal current year, implying an average EPS of -$0.92. EPS for the following year is -$1.01, with 9.0 analysts recommending between -$0.6 and -$1.36.
Revenue Estimates
8 analysts predict $18.4M in revenue for the current quarter. It ranges from a high estimate of $19.3M to a low estimate of $18M. As of the current estimate, Y-Mabs Therapeutics Inc’s year-ago sales were $22.8MFor the next quarter, 8 analysts are estimating revenue of $21.02M. There is a high estimate of $22.65M for the next quarter, whereas the lowest estimate is $19.12M.
A total of 10 analysts have provided revenue estimates for YMAB’s current fiscal year. The highest revenue estimate was $86M, while the lowest revenue estimate was $78.07M, resulting in an average revenue estimate of $82.41M. In the same quarter a year ago, actual revenue was $87.69MBased on 9 analysts’ estimates, the company’s revenue will be $95.19M in the next fiscal year. The high estimate is $129.8M and the low estimate is $85.88M.
